PERXOAG Trademark

Trademark Overview

On Thursday, August 17, 2006, a trademark application was filed for PERXOAG with the United States Patent and Trademark Office. The USPTO has given the PERXOAG trademark a serial number of 79028845. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Thursday, August 18, 2016. This trademark is owned by sanofi-aventis. The PERXOAG trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the prevention and treatment of cardiovascular diseases, and anti-thrombotic preparations
perxoag

General Information

Serial Number79028845
Word MarkPERXOAG
Filing DateThursday, August 17, 2006
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateThursday, August 18, 2016
Registration Number3286624
Registration DateTuesday, August 28, 2007
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, June 12, 2007

Trademark Statements

Goods and Servicespharmaceutical preparations for the prevention and treatment of cardiovascular diseases, and anti-thrombotic preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, April 4, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSANOFI
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressFR
Party Namesanofi-aventis
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFR
Party Namesanofi-aventis
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFR

Trademark Events

Event DateEvent Description
Friday, March 3, 2017NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Friday, March 3, 2017DEATH OF INTERNATIONAL REGISTRATION
Saturday, June 20, 2015TOTAL INVALIDATION PROCESSED BY THE IB
Tuesday, May 5, 2015GENERIC MADRID TRANSACTION SENT TO IB
Tuesday, May 5, 2015GENERIC MADRID TRANSACTION CREATED
Thursday, December 4, 2014TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, April 4, 2014CANCELLED SECTION 71
Saturday, July 21, 2012CHANGE OF NAME/ADDRESS REC'D FROM IB
Saturday, December 10, 2011CHANGE OF NAME/ADDRESS REC'D FROM IB
Saturday, September 20, 2008FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, December 17, 2007FINAL DISPOSITION NOTICE SENT TO IB
Sunday, December 16, 2007FINAL DISPOSITION PROCESSED
Wednesday, December 5, 2007FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 28, 2007REGISTERED-PRINCIPAL REGISTER
Tuesday, June 12, 2007PUBLISHED FOR OPPOSITION
Wednesday, May 23, 2007NOTICE OF PUBLICATION
Monday, April 9, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 4, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 16, 2007AMENDMENT FROM APPLICANT ENTERED
Friday, March 16, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 16, 2007APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, March 16, 2007ASSIGNED TO LIE
Thursday, February 8, 2007PAPER RECEIVED
Wednesday, January 17, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 15, 2006REFUSAL PROCESSED BY IB
Wednesday, November 29, 2006NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, November 29, 2006REFUSAL PROCESSED BY MPU
Tuesday, November 28, 2006NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, November 27, 2006NON-FINAL ACTION WRITTEN
Monday, November 27, 2006ASSIGNED TO EXAMINER
Friday, October 27, 2006NEW APPLICATION ENTERED IN TRAM
Thursday, October 26, 2006SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

perxoag preparations anti thrombotic diseases treatment prevention pharmaceutical cardiovascular